ALXN

Alexion Pharmaceuticals Inc.

This asset is no longer available for investment.

View all assets

Price

return (12m)

0.00%

p/e

58.89

p/bv

3.23

DIVIDEND YIELD

0.00%

ALXN price

Alexion Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALXN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ALXN

Valuation

P/E

58.89

Sector -2.34

Industry 0.52

P/BV

3.23

Sector 2.17

Industry 2.37

P/Revenue (PSR)

6.41

Sector 2.00

Industry 2.42

EV/EBITDA

55.45

Sector -23.69

Industry -19.70

EV/EBIT

62.11

Sector -36.60

Industry -19.56

P/EBITDA

43.19

Sector -0.10

Industry 1.15

P/EBIT

65.39

Sector -2.08

Industry -0.30

P/Total Assets

2.15

Sector 1.18

Industry 1.29

P/Net Current Assets

172.02

Sector -10.91

Industry -12.19

P/Working Capital

7.99

Sector 0.09

Industry 3.28

EPS

3.10

Sector -0.93

Industry -0.75

BVPS

56.50

Sector 3.87

Industry 5.09

Efficiency

Gross Margin

90.94%

Sector 44.28%

Industry 49.44%

EBITDA Margin

43.10%

Sector -291.45%

Industry -51.49%

EBIT Margin

38.48%

Sector -195.44%

Industry -51.11%

Operating Margin

47.07%

Sector -25.72%

Industry -28.72%

Net Profit Margins

10.89%

Sector -30.19%

Industry -32.17%

Asset Turnover

0.09

Sector 0.12

Industry 0.14

Profitability

ROE

5.48%

Sector -34.71%

Industry -35.29%

ROA

3.66%

Sector -28.76%

Industry -26.40%

ROIC

19.10%

Sector -441.27%

Industry -96.96%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

4.52

Sector 1.87

Industry 1.96

Net Debt / EBITDA

-1.48

Sector -2.18

Industry -4.73

Net Debt / EBIT

-1.65

Sector -0.74

Industry -1.94

Net Debt / Equity

-0.08

Sector -0.34

Industry -0.27

Gross Debt / Equity

0.19

Sector -0.64

Industry 0.20

Equity/Assets

0.67

Sector 0.43

Industry 0.45

Liabilities/Assets

0.33

Sector 0.46

Industry 0.51

Growth

5Y Revenue CAGR

30.78%

Sector -

Industry -

5Y Earnings CAGR

1.40%

Sector -

Industry -

FAIR VALUE OF Alexion Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$62.78

Upside Return potential.

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ALXN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ALXN Alexion Pharmaceuticals Inc.	$0.00	-	0.00%	58.89	3.23	5.48%	10.89%
EW Edwards Lifesciences Corp.	$78.21	12.69%	0.00%	45.55	4.82	10.58%	17.34%
BSX Boston Scientific Corp.	$63.80	-31.89%	0.00%	18.45	2.54	13.78%	17.29%
ABT Abbott Laboratories	$101.06	-18.35%	0.00%	25.64	3.09	12.06%	13.91%
ABMD Abiomed Inc.	$0.00	-	0.00%	64.27	11.14	17.32%	24.84%
ALGN Align Technology Inc.	$184.69	12.52%	0.00%	27.86	2.89	10.36%	10.50%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALXN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Alexion Pharmaceuticals

Alexion Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

34 years

Founded: 1992

1996

Time since IPO - 30 years

3.837

Employees

Alexion Pharmaceuticals Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $40.15 billion, with shareholders equity totaling $12.43 billion.

The company employs approximately 3.837 people and operates in the Saúde sector, within the Principais Medicamentos industry.

Over the past 12 months, Alexion Pharmaceuticals Inc. reported $6.26 billion in revenue, generating net income of $681.80 million.

Key financial metrics include a P/E ratio of 58.89, a price-to-book (P/B) ratio of 3.23, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALXN.

Market cap

$40.15 billion

Net worth

$12.43 billion

$12,431,000,000.00

Assets

$18.65 billion

$18,650,200,000.00

Total Shares Outstanding

220.00 million

220,000,000

Average Daily Trading Volume

$5.81 million

$5,809,888.66

Sector

Saúde

Industry

Principais Medicamentos

ALXN

ALXN revenue and profits

Financial Results ALXN

DRAG THE FRAME TO SEE MORE DATA

ALXN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$77.63 34,88% (12M)

P/E

46.88

2.46%

ROE

3.78%

P/BV

1.77

CI - Cigna

$272.65 --5,23% (12M)

P/E

11.58

2.16%

ROE

15.39%

P/BV

1.78

CNC - Centene

$37.26 38,72% (12M)

P/E

-4.98

0.00%

ROE

-29.93%

P/BV

1.49

HUM - Humana

$196.30 --14,19% (12M)

P/E

42.07

0.89%

ROE

6.06%

P/BV

2.55

SNY - Sanofi

$47.64 --3,72% (12M)

P/E

7.21

4.00%

ROE

17.79%

P/BV

1.28

LLY - Eli Lilly

$923.03 21,62% (12M)

P/E

41.74

0.55%

ROE

81.02%

P/BV

33.82

HCA - HCA Healthcare

$498.78 47,18% (12M)

P/E

12.41

0.80%

ROE

-228.14%

P/BV

-28.31

NVS - Novartis

$153.41 34,63% (12M)

P/E

21.74

2.01%

ROE

34.77%

P/BV

7.56